These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18657803)

  • 21. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
    Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
    J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple pharmacokinetics subroutine for modeling double peak phenomenon.
    Mirfazaelian A; Mahmoudian M
    Biopharm Drug Dispos; 2006 Apr; 27(3):119-24. PubMed ID: 16400712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
    Germani M; Crivori P; Rocchetti M; Burton PS; Wilson AG; Smith ME; Poggesi I
    Eur J Pharm Sci; 2007 Jul; 31(3-4):190-201. PubMed ID: 17481865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling of absorption.
    Woltosz WS; Bolger MB; Lukacova V
    Methods Mol Biol; 2012; 929():313-36. PubMed ID: 23007435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of a simulated annealing algorithm to fit compartmental models with an application to fractal pharmacokinetics.
    Marsh RE; Riauka TA; McQuarrie SA
    J Pharm Pharm Sci; 2007; 10(2):168-79. PubMed ID: 17706176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.
    Zhao P; Rowland M; Huang SM
    Clin Pharmacol Ther; 2012 Jul; 92(1):17-20. PubMed ID: 22713733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling interindividual variation in physiological factors used in PBPK models of humans.
    Price PS; Conolly RB; Chaisson CF; Gross EA; Young JS; Mathis ET; Tedder DR
    Crit Rev Toxicol; 2003; 33(5):469-503. PubMed ID: 14594104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach.
    Chiu WA; Okino MS; Evans MV
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):36-60. PubMed ID: 19660485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly.
    Evans MV; Chiu WA; Okino MS; Caldwell JC
    Toxicol Appl Pharmacol; 2009 May; 236(3):329-40. PubMed ID: 19249323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program.
    Tanswell P; Koup J
    Int J Clin Pharmacol Ther Toxicol; 1993 Oct; 31(10):514-20. PubMed ID: 8262691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stochasticity in physiologically based kinetics models: implications for cancer risk assessment.
    Péry AR; Bois FY
    Risk Anal; 2009 Aug; 29(8):1182-91. PubMed ID: 19508449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple computational approach to model parameter estimation.
    Blardi P; Barbini P; Di Perri T
    Int J Clin Pharmacol Res; 1993; 13(6):325-30. PubMed ID: 8088933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models.
    Toshimoto K
    Drug Metab Pharmacokinet; 2024 Jun; 56():101011. PubMed ID: 38833901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based analysis of survival experiments with zero and non-zero final survivors.
    Sühnel J
    Z Versuchstierkd; 1989; 32(4):157-65. PubMed ID: 2626881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonlinear mixed effects pharmacokinetic/pharmacodynamic analysis of the anticonvulsant ameltolide (LY201116) in a canine seizure model.
    Territo PR; Shannon HE; Newhall K; Barnhart SD; Peters SC; Engleking DR; Bin T; Burnett TJ; Rodewald JM; Abdul-Karim B; Freise KJ
    J Vet Pharmacol Ther; 2008 Dec; 31(6):562-70. PubMed ID: 19000280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An implementation of the Expectation-Maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME.
    Yates JW
    Comput Methods Programs Biomed; 2009 Oct; 96(1):49-62. PubMed ID: 19410328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically based pharmacokinetic models: mathematical fundamentals and simulation implementations.
    Hoang K
    Toxicol Lett; 1995 Sep; 79(1-3):99-106. PubMed ID: 7570678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models.
    Graham G; Gueorguieva I; Dickens K
    Comput Methods Programs Biomed; 2005 Jun; 78(3):237-49. PubMed ID: 15899308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
    Graf JF; Scholz BJ; Zavodszky MI
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):37-54. PubMed ID: 22161221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.